Home Cart Sign in  
Chemical Structure| 329773-35-5 Chemical Structure| 329773-35-5

Structure of Cinaciguat
CAS No.: 329773-35-5

Chemical Structure| 329773-35-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Cinaciguat is the first of a class of soluble guanylate cyclase (sGC) activators in clinical development for acute decompensated heart failure.

Synonyms: BAY 58-2667

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Cinaciguat

CAS No. :329773-35-5
Formula : C36H39NO5
M.W : 565.70
SMILES Code : OC(C(C=C1)=CC=C1CN(CCCCC(O)=O)CCC(C=CC=C2)=C2OCC(C=C3)=CC=C3CCC4=CC=CC=C4)=O
Synonyms :
BAY 58-2667
MDL No. :MFCD18782678
InChI Key :WPYWMXNXEZFMAK-UHFFFAOYSA-N
Pubchem ID :9808022

Safety of Cinaciguat

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Cinaciguat

GPCR

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Type-1 diabetes mellitus model Oral 10 mg/kg Once daily for 8 weeks Cinaciguat treatment effectively prevented DM related molecular and histological alterations and significantly improved systolic and diastolic function. Cardiovasc Diabetol. 2015 Oct 31;14:145
Wistar rats 5/6 nephrectomy model Oral 3000 ppm (approximately 50 mg/day) Once daily for 18 weeks To assess the potential of BAY 58-2667 in preventing cardiac and renal target organ damage in rats with 5/6 nephrectomy. Results showed that BAY 58-2667 significantly lowered blood pressure, reduced left ventricular hypertrophy, and improved renal function and morphology. Br J Pharmacol. 2006 Jul;148(6):853-9
Mice SMC-specific CYB5R3 KO mice Intraperitoneal injection 0.04 mg/kg and 0.4 mg/kg Once daily for several days To assess the effect of BAY 58-2667 on blood pressure, results showed that SMC CYB5R3–KO mice had a stronger hypotensive response to BAY 58-2667 JCI Insight. 2019 Oct 3;4(19):e129183
Mice Apo-sGC mice Intravenous injection 300 μg/kg Single dose, responses recorded 1-25 minutes post injection To investigate the effect of cinaciguat on blood pressure, results showed that cinaciguat had a more potent and longer-lasting BP-lowering effect in apo-sGC mice compared to WT mice Nat Commun. 2015 Oct 7;6:8482

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.84mL

1.77mL

0.88mL

17.68mL

3.54mL

1.77mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories